Kronos Bio, Inc. (NASDAQ:KRON) has presented positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data shows that KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors. The preliminary analysis included 28 patients who received doses from 10 mg up to 60 mg. The most prevalent treatment-emergent adverse events included nausea, vomiting and fatigue, all of which were grade 1/2.